Astrid Sissel Jørgensen

Astrid Sissel Jørgensen

Auto-generated profile, based on publicly available information

Astrid Sissel Jørgensen

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EBEmma Probst Brandum
Emma Probst Brandum
AJAstrid Sissel Jørgensen
Astrid Sissel Jørgensen
MRmette rosenkilde
mette rosenkilde
GHGertrud Malene Hjortø
Gertrud Malene Hjortø
Chemotactic cytokines—chemokines—control immune cell migration in the process of initiation and resolution of inflammatory conditions as part of the body’s defense system. Many chemokines also participate in pathological processes leading up to and exacerbating the inflammatory state characterizing chronic inflammatory diseases. In this review, we discuss the role of dendritic cells (DCs) and the central chemokine receptor CCR7 in the initiation and sustainment of selected chronic inflammatory diseases: multiple sclerosis (MS), rheumatoid arthritis (RA), and psoriasis. We revisit the binary role that CCR7 plays in combatting and progressing cancer, and we discuss how CCR7 and DCs can be harnessed for the treatment of cancer. To provide the necessary background, we review the differential roles of the natural ligands of CCR7, CCL19, and CCL21 and how they direct the mobilization of activated DCs to lymphoid organs and control the formation of associated lymphoid tissues (ALTs). We provide an overview of DC subsets and, briefly, elaborate on the different T-cell effector types generated upon DC–T cell priming. In the conclusion, we promote CCR7 as a possible target of future drugs with an antagonistic effect to reduce inflammation in chronic inflammatory diseases and an agonistic effect for boosting the reactivation of the immune system against cancer in cell-based and/or immune checkpoint inhibitor (ICI)-based anti-cancer therapy.

12 May 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
AJAstrid S. Jørgensen
Astrid S. Jørgensen
VDViktorija Daugvilaite
Viktorija Daugvilaite
KFKatia De Filippo
Katia De Filippo
CBChristian Berg
Christian Berg
MMMasa Mavri
Masa Mavri
MRmette rosenkilde
mette rosenkilde
Following the FDA-approval of the hematopoietic stem cell (HSC) mobilizer plerixafor, orally available and potent CXCR4 antagonists were pursued. One such proposition was AMD11070, which was orally active and had superior antagonism in vitro; however, it did not appear as effective for HSC mobilization in vivo. Here we show that while AMD11070 acts as a full antagonist, plerixafor acts biased by stimulating β-arrestin recruitment while fully antagonizing G protein. Consequently, while AMD11070 prevents the constitutive receptor internalization, plerixafor allows it and thereby decreases receptor expression. These findings are confirmed by the successful transfer of both ligands’ binding sites and action to the related CXCR3 receptor. In vivo, plerixafor exhibits superior HSC mobilization associated with a dramatic reversal of the CXCL12 gradient across the bone marrow endothelium, which is not seen for AMD11070. We propose that the biased action of plerixafor is central for its superior therapeutic effect in HSC mobilization.

1 March 2018 in General and Comparative Endocrinology
Verified
Journal Article
Closed access
AJAstrid Sissel Jørgensen
Astrid Sissel Jørgensen
MRmette rosenkilde
mette rosenkilde
GHGertrud Malene Hjortø
Gertrud Malene Hjortø

16 May 2018 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
AJAstrid S. Jørgensen
Astrid S. Jørgensen
PAPontian E Adogamhe
Pontian E Adogamhe
JLJulia M. Laufer
Julia M. Laufer
DLDaniel F. Legler
Daniel F. Legler
CVChristopher T. Veldkamp
Christopher T. Veldkamp
GHGertrud Malene Hjortø
Gertrud Malene Hjortø
CCL19 is more potent than CCL21 in inducing chemotaxis of human dendritic cells (DC). This difference is attributed to 1) a stronger interaction of the basic C‐terminal tail of CCL21 with acidic glycosaminoglycans (GAGs) in the environment and 2) an autoinhibitory function of this C‐terminal tail. Moreover, different receptor docking modes and tissue expression patterns of CCL19 and CCL21 contribute to fine‐tuned control of CCR7 signaling. Here, we investigate the effect of the tail of CCL21 on chemokine binding to GAGs and on CCR7 activation. We show that transfer of CCL21‐tail to CCL19 (CCL19CCL21‐tail) markedly increases binding of CCL19 to human dendritic cell surfaces, without impairing CCL19‐induced intracellular calcium release or DC chemotaxis, although it causes reduced CCR7 internalization. The more potent chemotaxis induced by CCL19 and CCL19CCL21‐tail compared to CCL21 is not transferred to CCL21 by replacing its N‐terminus with that of CCL19 (CCL21CCL19‐N‐term). Measurements of cAMP production in CHO cells uncover that CCL21‐tail transfer (CCL19CCL21‐tail) negatively affects CCL19 potency, whereas removal of CCL21‐tail (CCL21tailless) increases signaling compared to full‐length CCL21, indicating that the tail negatively affects signaling via cAMP. Similar to chemokine‐driven calcium mobilization and chemotaxis, the potency of CCL21 in cAMP is not improved by transfer of the CCL19 N‐terminus to CCL21 (CCL21CCL19‐N‐term). Together these results indicate that ligands containing CCL21 core and C‐terminal tail (CCL21 and CCL21CCL19‐N‐term) are most restricted in their cAMP signaling; a phenotype attributed to a stronger GAG binding of CCL21 and defined structural differences between CCL19 and CCL21.

4 April 2023 in Science Signaling
Verified
Journal Article
Closed access
VKViktoria M. S. Kjær
Viktoria M. S. Kjær
VDViktorija Daugvilaite
Viktorija Daugvilaite
TSTomasz Stepniewski
Tomasz Stepniewski
CMChristian M. Madsen
Christian M. Madsen
AJAstrid S. Jørgensen
Astrid S. Jørgensen
MRmette rosenkilde
mette rosenkilde
The chemotactic G protein–coupled receptor GPR183 and its most potent endogenous oxysterol ligand 7α,25-dihydroxycholesterol (7α,25-OHC) are important for immune cell positioning in secondary lymphoid tissues. This receptor-ligand pair is associated with various diseases, in some cases contributing favorably and in other cases adversely, making GPR183 an attractive target for therapeutic intervention. We investigated the mechanisms underlying GPR183 internalization and the role of internalization in the main biological function of the receptor, chemotaxis. We found that the C terminus of the receptor was important for ligand-induced internalization but less so for constitutive (ligand-independent) internalization. β-arrestin potentiated ligand-induced internalization but was not required for ligand-induced or constitutive internalization. Caveolin and dynamin were the main mediators of both constitutive and ligand-induced receptor internalization in a mechanism independent of G protein activation. Clathrin-mediated endocytosis also contributed to constitutive GPR183 internalization in a β-arrestin–independent manner, suggesting the existence of different pools of surface-localized GPR183. Chemotaxis mediated by GPR183 depended on receptor desensitization by β-arrestins but could be uncoupled from internalization, highlighting an important biological role for the recruitment of β-arrestin to GPR183. The role of distinct pathways in internalization and chemotaxis may aid in the development of GPR183-targeting drugs for specific disease contexts.

Verified
Journal Article
Open access
PDF file
EBEmma Probst Brandum
Emma Probst Brandum
AJAstrid Sissel Jørgensen
Astrid Sissel Jørgensen
MCMarina Barrio Calvo
Marina Barrio Calvo
KSKatja Spiess
Katja Spiess
FPFrancis C. Peterson
Francis C. Peterson
GHGertrud Malene Hjortø
Gertrud Malene Hjortø
The chemokine receptor CCR7 and its ligands CCL19 and CCL21 regulate the lymph node homing of dendritic cells and naïve T-cells and the following induction of a motile DC-T cell priming state. Although CCL19 and CCL21 bind CCR7 with similar affinities, CCL21 is a weak agonist compared to CCL19. Using a chimeric chemokine, CCL19CCL21N-term|C-term, harboring the N-terminus and the C-terminus of CCL21 attached to the core domain of CCL19, we show that these parts of CCL21 act in a synergistic manner to lower ligand potency and determine the way CCL21 engages with CCR7. We have published that a naturally occurring basic C-terminal fragment of CCL21 (C21TP) boosts the signaling of both CCL19 and CCL21. Boosting occurs as a direct consequence of C21TP binding to the CCR7 N-terminus, which seems to free chemokines with basic C-termini from an unfavorable interaction with negatively charged posttranslational modifications in CCR7. Here, we confirm this using a CCL19-variant lacking the basic C-terminus. This variant displays a 22-fold higher potency at CCR7 compared to WT CCL19 and is highly unaffected by the presence of C21TP. WT CCL19 has a short basic C-terminus, CCL21 a longer one. Here, we propose a way to differentially boost CCL19 and CCL21 activity as short and long versions of C21TP boost CCL19 activity, whereas only a long C21TP version can boost chemokines with a full-length CCL21 C-terminus.